Wang J.,Geriatric Institute of Jiangsu Province |
Zhou W.,Geriatric Institute of Jiangsu Province |
Xu L.,Nanjing Medical University |
Yang M.,Geriatric Institute of Jiangsu Province |
And 4 more authors.
Chinese Journal of Lung Cancer | Year: 2011
Background and objective Malignant tumors often combined with venous thrombosis and pulmonary embolism, especially in lung cancer. It has been proven that, the mechanisms and risk factors for lung cancer patients contracting pulmonary embolism are unclear. The aim of this study is to summarize the clinical data on 54 patients with lung cancer and concomitant pulmonary embolism, and to analyze the risk factors and prognosis of lung cancer with pulmonary thromboembolism (PTE). Methods From April 1999 to January 2010, the clinical presentation of lung cancer patients with PTE from the Jiangsu Cancer Hospital and the Jiangsu Gerontic Institute were evaluated in the present retrospective study. Univariate analysis was conducted to determine the possible associated variables. Conditional logistic regression analysis was applied to explore risk factors of pulmonary embolism. Patient survival was also compared with matched controls via a Log-rank test. Results A total of 54 lung cancer patients with PTE, matched with 162 lung cancer patients as controls, were included. In the univariate analysis, a P<0.20 was considered as possible risk factor, which was included into the logistic regression model. The logistic regression model showed that the OR combined with pulmonary embolism was 2.64 in patients receiving chemotherapy, 2.25 in patients with stage III-IV disease, 2.39 in patients combined with chronic obstructive pulmonary disease (COPD), 2.12 in patients with adenocarcinoma, 2.10 in patients with serum hemoglobin>140 g/L, and 1.76 in patients with central venous catheters. A significant difference was observed among the groups that received chemotherapy, adenocarcinoma, stage III-IV disease and high henoglobin (P<0.05). The survival time in patients with pulmonary embolism was remarkably lower than that in patients without pulmonary embolism (P=0.02). Conclusion Chemotherapy, late stage disease and high serum hemoglobin are important risk factors for lung cancer patients with concomitant pulmonary embolism. The survival time of these patients is significantly lower than that in patients without pulmonary embolism. Source
Qian Y.,Nanjing Medical University |
Pei D.,Nanjing Medical University |
Cheng T.,Nanjing Medical University |
Wu C.,Nanjing Medical University |
And 6 more authors.
Medical Oncology | Year: 2015
CD137 ligand (CD137L), a member of the tumor necrosis factor superfamily, is expressed on antigen-presenting cells and also on various tumor cells. Crosslinking of CD137L transmits signals that evoke different cellular responses in a variety of tumor cells. This study was designed to investigate signaling pathways activated by CD137L and its physiologic role in the progression of NSCLC. We investigated the expression of CD137L in tissues from 102 cases of human non-small cell lung cancer (NSCLC) using immunohistochemistry and analyzed the correlation with clinicopathological features using Fisher’s exact test and overall survival using Kaplan–Meier curves and the log-rank test. The effect of CD137L reverse signaling induced by recombinant human CD137-Fc protein on NSCLC cell lines was assessed using proliferation and apoptosis assays, flow cytometry and Western blotting. Positive CD137L expression was observed in 53/102 (52.0 %) of the NSCLC samples and correlated with early TNM stage (P = 0.046), well-differentiated tumors (P = 0.009) and better overall survival (P = 0.004). Moreover, induction of CD137L reverse signaling using CD137-Fc inhibited proliferation and induced apoptosis and cell cycle arrest in H1650 cells, which express high levels of CD137L; CD137L reverse signaling had no significant effects in PC9 cells, which express low levels of CD137L. In addition, CD137L reverse signaling-induced apoptosis occurred via activation of the intrinsic pathway and depended on phosphorylation of JNK. This study demonstrates a hitherto unrecognized role for CD137L reverse signaling in the development of NSCLC and indicates that CD137L has potential as a novel therapeutic target in NSCLC. © 2015, Springer Science+Business Media New York. Source